Point72 Asset Management’s Myriad Genetics MYGN Stock Holding History

Point72 Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.31M	Sell	957,901 -274,767	-22%	-$1.43M	0.01%	1796
2025 Q4	$7.58M	Buy	1,232,668 +158,705	+15%	+$1.15M	0.01%	1534
2025 Q3	$7.76M	Buy	1,073,963 +535,903	+100%	+$3.18M	0.01%	901
2025 Q2	$2.86M	Buy	538,060 +353,060	+191%	+$2.09M	0.01%	1164
2025 Q1	$1.64M	Sell	185,000 -163,604	-47%	-$1.96M	﹤0.01%	1304
2024 Q4	$4.78M	Sell	348,604 -715,107	-67%	-$13.2M	0.01%	965
2024 Q3	$29.1M	Buy	1,063,711 +224,255	+27%	+$6.07M	0.07%	314
2024 Q2	$20.5M	Buy	839,456 +61,260	+8%	+$1.34M	0.05%	395
2024 Q1	$16.6M	Buy	+778,196	New	+$16.7M	0.04%	525
2023 Q4	–	Sell	-2,636	Closed	-$42.3K	–	2582
2023 Q3	$42.3K	Buy	2,636 +2,601	+7,431%	+$49.5K	﹤0.01%	2169
2023 Q2	$816	Buy	+35	New	+$764	﹤0.01%	2008
2023 Q1	–	Sell	-26,800	Closed	-$389K	–	2439
2022 Q4	$389K	Sell	26,800 -377,608	-93%	-$7.04M	﹤0.01%	1174
2022 Q3	$7.72M	Buy	404,408 +175,163	+76%	+$4.02M	0.03%	590
2022 Q2	$4.17M	Buy	229,245 +81,648	+55%	+$1.7M	0.02%	754
2022 Q1	$3.72M	Buy	+147,597	New	+$3.78M	0.01%	763
2021 Q4	–	Sell	-239,493	Closed	-$7.73M	–	1226
2021 Q3	$7.73M	Sell	239,493 -142,312	-37%	-$4.73M	0.03%	546
2021 Q2	$11.7M	Sell	381,805 -16,043	-4%	-$464K	0.05%	414
2021 Q1	$12.1M	Buy	397,848 +28,740	+8%	+$816K	0.06%	386
2020 Q4	$7.3M	Buy	369,108 +345,029	+1,433%	+$5.57M	0.04%	513
2020 Q3	$314K	Buy	+24,079	New	+$305K	﹤0.01%	850
2020 Q2	–	Sell	-141,500	Closed	-$2.02M	–	943
2020 Q1	$2.02M	Buy	141,500 +124,839	+749%	+$2.64M	0.02%	504
2019 Q4	$454K	Sell	16,661 -121,253	-88%	-$3.34M	﹤0.01%	781
2019 Q3	$3.95M	Sell	137,914 -844,687	-86%	-$24.6M	0.02%	496
2019 Q2	$27.3M	Buy	982,601 +359,488	+58%	+$10.2M	0.14%	181
2019 Q1	$20.7M	Sell	623,113 -313,394	-33%	-$9.54M	0.09%	242
2018 Q4	$27.2M	Buy	936,507 +326,187	+53%	+$11.7M	0.13%	195
2018 Q3	$28.1M	Sell	610,320 -225,880	-27%	-$10M	0.12%	226
2018 Q2	$31.2M	Sell	836,200 -46,674	-5%	-$1.58M	0.12%	209
2018 Q1	$26.1M	Buy	882,874 +18,926	+2%	+$640K	0.11%	243
2017 Q4	$29.7M	Buy	+863,948	New	+$29.1M	0.13%	219
2015 Q2	–	Sell	-153,400	Closed	-$5.43M	–	805
2015 Q1	$5.43M	Sell	153,400 -206,900	-57%	-$7.41M	0.04%	426
2014 Q4	$12.3M	Buy	+360,300	New	+$12.8M	0.09%	291

Other funds holding MYGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Asset Management's MYGN Position: Q1 2026 in Review

Point72 Asset Management reduced its Myriad Genetics (MYGN) stake by 22% in Q1 2026, selling an estimated $1.43M and leaving 957,901 shares worth $4.31M. The position accounts for 0.01% of the portfolio, ranked #1796.

Point72 Asset Management first reported a position in MYGN in Q4 2014 and has held it in 32 quarters since. The position peaked at $31.2M in Q2 2018. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

Point72 Asset Management held 957,901 shares of Myriad Genetics worth $4.31M as of Q1 2026.
Point72 Asset Management sold 274,767 Myriad Genetics shares in Q1 2026, an estimated $1.43M.
Myriad Genetics made up 0.01% of Point72 Asset Management's portfolio in Q1 2026, its #1796 holding.
Point72 Asset Management first reported a position in Myriad Genetics in Q4 2014 and has held it in 32 quarters since.
Point72 Asset Management's Myriad Genetics position peaked at $31.2M in Q2 2018.
202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.